Comparison of the efficacy between DEB(drug-eluting-bead)-TACE and hepasphere with the use of epirubicin :a randomized prospective phase 2 trial

Comparison of the efficacy between DEB(drug-eluting-bead)-TACE and hepasphere with the use of epirubicin :a randomized prospective phase 2 trial - BHEP

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013966

Enrollment

Registered

2014-05-15

Start date

2014-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

DC bead hepasphere

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with histologically or radiographically diagnosed HCC patients over 20 years old with informed consent form singed patients must have a life expectancy of at least 6 months EOCG performanc status 0 or 1 Patients who are recived systemic or

Exclusion criteria

Exclusion criteria: patients with extrahepatic and metastasis of the lymph node macroscopic vascular invasion active serious infection exept for hepatic B or C infection active cancer Pregnant or lacting women

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
Time to local progression MST TE mRESICT	—

Countries

Japan

Contacts

Public Contactshigeo shimose

kurume university gastroenterology

shimose_shigeo@med.kurume-u.ac.jp0942-35-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026